Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

CAm2029

- PMLiVE

Eli Lilly and Camurus enter cardiometabolic health partnership worth up to $870m

The deal gives Lilly exclusive global rights to incretin products based on Camurus’ technology

- PMLiVE

Camurus shares positive late-stage results for investigational acromegaly treatment

The rare disease has an estimated prevalence of approximately 60 cases per million

- PMLiVE

Novartis’ acromegaly therapy cleared by FDA

Signifor LAR shows superior efficiency to older treatments

- PMLiVE

Novartis gets EU nod for rare disease drug Signifor

Long-acting formulation of drug approved for growth disorder acromegaly

Novartis building

Novartis plans filings for acromegaly candidate

Could add to Signifor’s indications

Roche - Basel

Roche licenses Chiasma’s acromegaly drug in $595m deal

Alternative to injection for hormonal disorder

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links